AYTU Aytu Biopharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AYTU

Price (delayed)

$2.145

Market cap

$23.02M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.55

Enterprise value

$18.12M

?
Relative Growth: Rel. Growth: 4
Relative Strength: Rel. Strength: 39
Relative Valuation: Rel. Valuation: 38
Relative Profitability: Rel. Profitability: 12
Highlights
Aytu Biopharma's equity has surged by 147% QoQ
Aytu Biopharma's quick ratio has increased by 12% YoY but it has decreased by 9% from the previous quarter
The company's net income fell by 39% QoQ
AYTU's EPS is down by 35% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Peers: CGEM LQDT

Key stats

What are the main financial stats of AYTU

AYTU stock price

How has the Aytu Biopharma stock price performed over time
Intraday
2.63%
1 week
-4.24%
1 month
-15.88%
1 year
34.91%
YTD
-17.5%
QTD
-21.43%

Financial performance

How have Aytu Biopharma's revenue and profit performed over time
Revenue
$56.6M
Gross profit
$36.66M
Operating income
-$15.16M
Net income
-$34.06M
Gross margin
64.8%
Net margin
-60.2%
Aytu Biopharma's operating margin has shrunk by 93% QoQ
Aytu Biopharma's operating income has plunged by 75% from the previous quarter
The company's net margin has shrunk by 54% QoQ
The company's net income fell by 39% QoQ

Price vs fundamentals

How does AYTU's price correlate with its fundamentals

Growth

What is Aytu Biopharma's growth rate over time

Valuation

What is Aytu Biopharma stock price valuation
P/E
N/A
P/B
0.66
P/S
0.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.32
AYTU's EPS is down by 35% QoQ
Aytu Biopharma's equity has surged by 147% QoQ
The P/B is 42% below the last 4 quarters average of 1.1 but 7% above the 5-year quarterly average of 0.6
AYTU's P/S is 30% above its 5-year quarterly average of 0.3 but 2.5% below its last 4 quarters average of 0.4
AYTU's revenue is down by 14% YoY and by 10% QoQ

Efficiency

How efficient is Aytu Biopharma business performance
Aytu Biopharma's ROIC has plunged by 163% YoY and by 65% from the previous quarter
AYTU's ROS has shrunk by 62% QoQ
The ROA has contracted by 43% from the previous quarter
The ROE has contracted by 39% from the previous quarter

Dividends

What is AYTU's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AYTU.

Financial health

How did Aytu Biopharma financials performed over time
Aytu Biopharma's total assets is 46% higher than its total liabilities
Aytu Biopharma's total liabilities has decreased by 29% QoQ and by 14% YoY
Aytu Biopharma's quick ratio has increased by 12% YoY but it has decreased by 9% from the previous quarter
The company's debt is 38% lower than its equity
Aytu Biopharma's equity has surged by 147% QoQ
The debt to equity has plunged by 58% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.